-
mRNA vaccines: current trends and prospects
Time of Update: 2021-09-19
In addition to shortened development time and efficiency (at least for COVID), there are other advantages to using mRNA for preventive and therapeutic vaccines .
The production method of mRNA vaccine also has advantages, because mRNA synthesis is based on a mature in vitro transcription process in a cell-free system .
-
Where is the end of the three transformations of Chinese medicine?
Time of Update: 2021-09-19
At the same time, it is necessary to ensure the sound and sustainable development of China's pharmaceutical and biological industry, and promote the innovation of China's biopharmaceutical enterprises.
-
Yinming Biotechnology completes nearly US$50 million in A+ round of financing
Time of Update: 2021-09-19
Reference materials:Reference materials: [1]Yinming has completed nearly US$50 million in Series A+ financing to accelerate clinical trials of blockbuster pipeline drug candidates.
com/s/yT7w8y7qyb1hno6ZpkEUTQ[1]Yinming has completed nearly US$50 million in Series A+ financing to accelerate clinical trials of blockbuster pipeline drug candidates.
-
18 new varieties passed the consistency evaluation, with 3 being the first
Time of Update: 2021-09-19
According to the incomplete statistics of the Medical Cloud Studio, there are currently 3,029 product regulations that have passed the consistency evaluation, and 353 product regulations have been evaluated by more than three (including three).
-
The highly competitive KRAS target: Me-too drugs can also be differentiated
Time of Update: 2021-09-19
Mirati non-small cell lung cancer A latecomer in this field, Cardiff Oncology evades its edge: on September 8th, it announced the early data of its drug candidate onvansertib on metastatic colorectal cancer (mCRC) , showing that compared with the standard of treatment, partial response and no disease progression prolonged Lifetime .
-
The sixth batch of national procurement began to report
Time of Update: 2021-09-19
The sixth batch of national procurement (insulin) special projects will enter the hospital reporting stage today, and chemical drugs will be collected or in the queue .
-
Kanghong has developed a market of over 2 billion!
Time of Update: 2021-09-19
According to data from Meinenet, pramipexole's market share ranks first among the top 10 generic names of anti-Parkinson's disease drugs in China's public medical institutions in 2020 .
Among the TOP10 generic names of anti-Parkinson's disease drugs, pramipexole ranks first in market share .
-
Ten indications have been added to the four domestically produced PD-1s. The medical insurance negotiations are approaching. How much is the decline this year?
Time of Update: 2021-09-19
In addition to the two included in medical insurance, BeiGene announced on January 14 this year that NMPA has approved its anti-PD-1 antibody tislelizumab combined with two chemotherapy regimens for the treatment of first-line advanced squamous non-small cell lung cancer (NSCLC ) Patients .
-
Novo Nordisk, Eli Lilly, Gan Li and other ten pharmaceutical companies will be fighting soon!
Time of Update: 2021-09-19
On September 10, Shanghai Sunshine Pharmaceutical Purchasing Network released the sixth batch of nationally organized drug centralized procurement (insulin special) related companies and product lists, involving Novo Nordisk, Eli Lilly, Sanofi, Tonghua Dongbao, Ganli Pharmaceutical, 81 products from 10 companies including United Laboratories, Tianmai Biological, Yuheng Pharmaceutical, Wanbang Pharmaceutical and Dongyang Pharmaceutical .
-
FDA expands the list of targets for violations for the first time: researchers who fail to report clinical trial results on time will be punished
Time of Update: 2021-09-19
Recently, the FDA warned for the first time that it would impose a fine on the PI of a clinical trial because it failed to submit the research results as required by the federal law as scheduled .
-
Blockbuster: The first clinical results of the first domestic CD3 recruiting bi-antibody phase I are released
Time of Update: 2021-09-19
This is Wuhan Youzhiyou, and it is also the first time that a domestic enterprise independently develops clinical data on CD3 recruiting antibodies Disclosure .
The results published this time are the phase I clinical trial results of Wuhan Youzhiyou EpCAM/CD3 dual antibody for the treatment of patients with malignant ascites .
-
Haisco introduces Lorecivivint, a new osteoarthritis drug for US$140 million
Time of Update: 2021-09-19
On September 13, Haisco announced the signing of a cooperation agreement with Biosplice Therapeutics of the United States for the treatment of osteoarthritis, the first innovative drug Lorecivivint, and obtained Lorecivivint's exclusive development, registration and commercialization rights in China .
-
Junshengtai HTD1801 officially launches clinical trials in China
Time of Update: 2021-09-19
In May of this year, HTD1801 was approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration to carry out clinical trials in China to improve the blood glucose control of patients with type 2 diabetes, further accelerating the global simultaneous development of HTD1801 .
-
Co-founded by Dr. Wang Xiaodong!
Time of Update: 2021-09-19
RIP1 inhibitor According to the official website of Viterilon, in animal experiments, inhibiting RIP1 kinase through small molecule drugs or gene editing can effectively prevent or reduce the development of a series of diseases , including multiple sclerosis (EAE model), Alzheimer's disease, amyotrophic lateral sclerosis, systemic inflammatory response syndrome .
-
2021 ESMO: Corning Jerry announces the latest clinical data of two dual antibodies, PD-L1/CTLA-4 dual antibodies will be reported for production in the first half of 2022
Time of Update: 2021-09-19
Conclusion: KN046 combined with lenvatinib shows good safety and preliminary efficacy, including good anti-tumor activity, higher ORR and may further extend the survival period of patients with advanced hepatocellular carcinoma .
-
The price of "anti-cancer drug" PD-1 penetrates the floor. Why are pharmaceutical companies still pouring into this red sea?
Time of Update: 2021-09-19
In this regard, retrospectively, it is believed that even if the drug companies that have already "on the car" are slow to market, they can directly use their own products when they develop new tumor drugs that require PD-1 combination, so as to firmly control it.
-
Countdown!
Time of Update: 2021-09-19
Starting from January 1, 2022, all the 305 varieties of non-ethnic medicines in the "Xinjiang Uygur Autonomous Region and Xinjiang Production and Construction Corps Drug Catalog for Basic Medical Insurance, Work Injury Insurance and Maternity Insurance" self-supplemented medicines will be transferred out of the scope of medical insurance payment .
-
Paizhen Biotech announces that Asia's first cGMP-level AAV production base with a capacity of 4000L has been put into full production
Time of Update: 2021-09-19
(hereinafter referred to as PackGene or PackGene) announced that it has a cGMP-level AAV gene therapy vector production base with a total area of 8,000 square meters, a production capacity of 4000L, and "Single-use Technology" (Single-use Technology).
-
1.5 billion injections!
Time of Update: 2021-09-19
On September 9, Haisco issued an announcement that its wholly-owned subsidiary, Liaoning Haisco Pharmaceuticals, had obtained approval for its supplementary application for the consistency evaluation of cefmetazole sodium for injection, making it the second company to review the product .
-
Rongchang's US$2.6 billion partnership ranks first, surpassing major pharmaceutical companies such as Roche and Daiichi Sankyo. Who will be among the top 10 ADC drugs in the world in 2021?
Time of Update: 2021-09-18
In 2019, Roche’s second ADC drug Polivy was approved for marketing by the FDA, combined with bendamustine and rituximab, for relapsed or refractory diffuse large B-cell lymphoma that had previously received at least 2 therapies (R/R DLBCL) patients .
